News Sentiment

VANI sentiment intelligence

Vivani Medical Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.36 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+7.9% over one week, +23.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction 7.9% Price confirming higher
Trend fit Trend inactive 23.6% over four weeks
Fair value 6.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 30
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 6
TradingView 5
Investing.com 4
MarketBeat 3
GlobeNewswire 3
Moomoo 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 10
Deals and strategy 9
Analyst action 6
Balance sheet 2
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
GlobeNewswire Direct company coverage

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

Vivani Medical, Inc. announced that it will present at the Emerging Growth Conference on July 15, 2026, at 4:10 p.m. Eastern Time. CEO Adam Mendelsohn will provide a company update on their miniature, GLP-1 drug implants designed for once- or twice-yearly administration for metab

Tone
Positive 63/100
Event
Market update
Published
15 Jul 2026 00:14
Source
GlobeNewswire
Stock Titan Direct company coverage

Vivani CEO to give company update in July 15 webcast

Vivani Medical (NASDAQ: VANI) announced that its CEO, Adam Mendelsohn, Ph.D., will present a company update at the Emerging Growth Conference on July 15, 2026, at 4:10 p.m. Eastern Time. The presentation will include an interactive session with live Q&A, and an archived webcast w

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:10
Source
Stock Titan
CNBC Direct company coverage

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Vivani Medical is developing a tiny GLP-1 implant designed to help patients maintain weight loss long-term, addressing issues like injection fatigue and treatment adherence common with existing GLP-1 drugs. The implant, containing semaglutide, is intended as a maintenance therapy

Tone
Positive 63/100
Event
Market update
Published
12 Jul 2026 11:11
Source
CNBC
Investing.com Direct company coverage

H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal

H.C. Wainwright has reiterated a Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk to evaluate NPM-139, Vivani's semaglutide drug implant for chronic weight management. This agreement is seen as external valid

Tone
Positive 71/100
Event
Analyst action
Published
10 Jul 2026 12:39
Source
Investing.com
Investing.com Australia Direct company coverage

H.C. Wainwright reiterates Vivani Medical stock rating on Novo deal By Investing.com

H.C. Wainwright has reiterated its Buy rating and a $3.50 price target for Vivani Medical (NASDAQ:VANI) following the company's agreement with Novo Nordisk. Vivani Medical's stock surged 24% over the past week after announcing a deal for Novo Nordisk to evaluate NPM-139, Vivani’s

Tone
Positive 71/100
Event
Analyst action
Published
10 Jul 2026 12:10
Source
Investing.com Australia
MarketBeat Direct company coverage

Analysts Set Expectations for Vivani Medical Q1 Earnings

HC Wainwright initiated Q1 2027 earnings estimates for Vivani Medical (NASDAQ:VANI) at a loss of $0.07 per share, maintaining a Buy rating and a $3.50 price target. Despite this, the broader analyst view is more cautious with an average "Hold" rating and a $3.75 price target. The

Tone
Positive 62/100
Event
Analyst action
Published
10 Jul 2026 12:10
Source
MarketBeat
Barchart.com Direct company coverage

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical has signed an agreement with Novo Nordisk to evaluate NPM-139, Vivani’s ultra long-acting semaglutide implant for chronic weight management. This confirms Novo Nordisk's interest in assessing the NanoPortal™ technology and its semaglutide application. Vivani plans

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 10:39
Source
Barchart.com
Baystreet.ca Direct company coverage

Vivani Flat on Hookup with Novo

Vivani Medical, Inc. announced a new agreement allowing Novo Nordisk to evaluate its semaglutide drug implant, NPM-139, for chronic weight management. Vivani expects to start a Phase 1 study for NPM-139 in mid-2026, comparing it to Wegovy® injections. This collaboration highlight

Tone
Positive 65/100
Event
Guidance
Published
07 Jul 2026 16:42
Source
Baystreet.ca
Stock Titan Direct company coverage

ClearOne (Nasdaq: CLRO) sets Cortigent merger, Vivani majority stake and $10–15M raise

ClearOne, Inc. has announced a definitive merger agreement to acquire Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical, Inc. Vivani will receive 12.5 million ClearOne shares, subsequently owning 59.4%–67.5% of the combined company, which will be renamed Cortigent Hold

Tone
Positive 63/100
Event
Deals and strategy
Published
06 Jul 2026 20:31
Source
Stock Titan
Sahm Direct company coverage

We're Keeping An Eye On Vivani Medical's (NASDAQ:VANI) Cash Burn Rate

Vivani Medical (NASDAQ:VANI) has a critical cash burn situation, with a cash runway of only about 9 months as of March 2026. The company, which is in an early stage without revenue, increased its cash burn by 22% over the last year. Shareholders face potential costly dilution if

Tone
Negative 24/100
Event
Balance sheet
Published
03 Jul 2026 21:09
Source
Sahm
Market source Direct company coverage

Vivani strikes reverse-merger agreement with ClearOne for BCI business

Vivani Medical has agreed to merge its neurotech subsidiary, Cortigent, with ClearOne to form a new publicly traded entity, Cortigent Holdings (CRGT), which will focus on brain-computer interface (BCI) technology. Under the agreement, Vivani will hold a majority stake in the new

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Jul 2026 11:40
Source
Market source
Moomoo Direct company coverage

Press Release: ClearOne Announces Entry Into Merger Agreement With Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

ClearOne, Inc. has announced a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical. This strategic transaction will result in Cortigent becoming a public company and is fully supported by Vivani Medical and Cortigent's existing investors.

Tone
Positive 66/100
Event
Deals and strategy
Published
02 Jul 2026 20:10
Source
Moomoo
Investing.com South Africa Direct company coverage

ClearOne stock surges 50% on Vivani merger deal By Investing.com

ClearOne Inc. shares surged over 52% after announcing a merger agreement with Cortigent Inc., a subsidiary of Vivani Medical Inc. Vivani will receive 12.5 million shares of ClearOne common stock, resulting in Vivani owning 59.4% to 67.5% of the combined company, which will be ren

Tone
Positive 72/100
Event
Deals and strategy
Published
02 Jul 2026 15:41
Source
Investing.com South Africa
MassDevice Direct company coverage

Vivani to sell neurotech subsidiary Cortigent to ClearOne

Vivani Medical announced a definitive agreement to sell its neurotech subsidiary, Cortigent, to ClearOne. The transaction will result in ClearOne being renamed "Cortigent Holdings, Inc." and trading under the Nasdaq ticker "CRGT," with Vivani retaining a majority stake. This move

Tone
Positive 72/100
Event
Deals and strategy
Published
02 Jul 2026 15:41
Source
MassDevice
Business Wire Direct company coverage

ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

ClearOne, Inc. has entered into a definitive merger agreement with Cortigent, Inc., a wholly-owned subsidiary of Vivani Medical. As part of the transaction, Cortigent will become a wholly-owned subsidiary of ClearOne, and ClearOne will conduct a financing round to raise $10 milli

Tone
Positive 67/100
Event
Deals and strategy
Published
02 Jul 2026 11:41
Source
Business Wire
TradingView Direct company coverage

Price to earnings forward of Vivani Medical, Inc. – NASDAQ:VANI

This article provides a financial overview of Vivani Medical, Inc. (NASDAQ: VANI), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of the report and there were no trades. The article is primarily a data page from T

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 07:39
Source
TradingView
Stock Titan Direct company coverage

Vivani Medical (NASDAQ: VANI) wins HREC nod for SLIM-1 semaglutide implant trial

Vivani Medical has received approval from Bellberry, an Australian human research ethics committee, to begin its SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant aimed at obesity and chronic weight management. The trial will assess the safety, tolerability, and ph

Tone
Positive 66/100
Event
Regulatory and legal
Published
30 Jun 2026 20:10
Source
Stock Titan